Researchers report that Klebsiella pneumoniae enriched in the guts of primary biliary cholangitis patients can translocate to ...

Autoimmune liver diseases (AILDs), including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing ...

The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible.

Autoimmune hepatitis quietly damages the liver for years before symptoms appear; specialists in Kenya warn of late diagnoses and urge early medical checks. [File, Standard] When people think about ...

Autoimmune liver diseases encompass a spectrum of chronic inflammatory conditions in which the body’s immune system targets hepatic cells or bile ducts. The principal entities are autoimmune hepatitis ...

The prevalence of AILD and IBD supports the gut-liver axis theory. Inflammatory bowel disease (IBD) and autoimmune liver disease (AILD) prevalence are significantly correlated, according to a study in ...

—A recent study provides genetic evidence linking a higher body mass index (BMI) to an increased risk of primary biliary cholangitis and autoimmune hepatitis but a decreased risk of primary sclerosing ...

The prevalence of type 2 diabetes in patients with autoimmune liver disease was 27.6%. Type 2 diabetes seems to reduce the risk of primary sclerosing cholangitis (PSC), and primary biliary cholangitis ...

Patients with autoimmune liver diseases reported non-adherence to prescribed therapies, with those with autoimmune hepatitis (AIH) reporting the highest rate of non‐adherence. The use of ...

With a novel mechanism of action, lixudebart exerts potent anti-inflammatory and anti-fibrotic effects to potentially prevent and reverse organ damage in ANCA-associated vasculitis (AAV) and numerous ...